NAF PLUS SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
23-04-2014
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
SODIUM FLUORIDE F 18
Tillgänglig från:
ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.
ATC-kod:
V09IX04
INN (International namn):
FLUDEOXYGLUCOSE (18F)
Dos:
7400MBq
Läkemedelsform:
SOLUTION
Sammansättning:
SODIUM FLUORIDE F 18 7400MBq
Administreringssätt:
INTRAVENOUS
Enheter i paketet:
30ML
Receptbelagda typ:
Schedule C
Terapiområde:
ROENTGENOGRAPHY
Produktsammanfattning:
Active ingredient group (AIG) number: 0153703002; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2017-05-10
Produktens egenskaper
PRODUCT MONOGRAPH
NaF Plus
Sodium Fluoride [
18
F] Injection, U.S.P.
Parenteral Solution
Diagnostic Radiopharmaceutical
Isologic Innovative Radiopharmaceuticals Ltd.
Date of Approval:
1855 32e Avenue, Lachine, Quebec H8T 3J1
Control # 171576
April 23, 2014
NaF Plus
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
DESCRIPTION
...........................................................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
4
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
5
DRUG
INTERACTIONS............................................................................................................
5
DOSAGE AND ADMINISTRATION
.......................................................................................
6
RADIATION DOSIMETRY
......................................................................................................
7
OVERDOSAGE
..........................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
8
STORAGE AND STABILITY
...................................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
.................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................
Läs hela dokumentet
